DK1466615T3 - Farmaceutisk præparat - Google Patents

Farmaceutisk præparat

Info

Publication number
DK1466615T3
DK1466615T3 DK04006076T DK04006076T DK1466615T3 DK 1466615 T3 DK1466615 T3 DK 1466615T3 DK 04006076 T DK04006076 T DK 04006076T DK 04006076 T DK04006076 T DK 04006076T DK 1466615 T3 DK1466615 T3 DK 1466615T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical preparation
pharmaceutical
preparation
Prior art date
Application number
DK04006076T
Other languages
Danish (da)
English (en)
Inventor
Alfred Dr Jonczyk
Astrid Dr Perschl
Simon Dr Goodman
Sigrid Dr Roesner
Jutta Dr Haunschild
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK1466615T3 publication Critical patent/DK1466615T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK04006076T 1998-09-16 1999-09-09 Farmaceutisk præparat DK1466615T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19842415A DE19842415A1 (de) 1998-09-16 1998-09-16 Pharmazeutische Zubereitung
PCT/EP1999/006654 WO2000015244A2 (de) 1998-09-16 1999-09-09 Pharmazeutische zubereitung enthaltend ein cyclo-peptide und ein chemotherapeutikum oder einen angiogeneseinhibitor

Publications (1)

Publication Number Publication Date
DK1466615T3 true DK1466615T3 (da) 2009-08-31

Family

ID=7881169

Family Applications (2)

Application Number Title Priority Date Filing Date
DK99969031T DK1113809T3 (da) 1998-09-16 1999-09-09 Farmaceutisk præparat indeholdende et cyclo-peptid og et kemoterapeutikum eller en angiogeneseinhibitor
DK04006076T DK1466615T3 (da) 1998-09-16 1999-09-09 Farmaceutisk præparat

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK99969031T DK1113809T3 (da) 1998-09-16 1999-09-09 Farmaceutisk præparat indeholdende et cyclo-peptid og et kemoterapeutikum eller en angiogeneseinhibitor

Country Status (31)

Country Link
US (1) US6683051B1 (ko)
EP (2) EP1113809B1 (ko)
JP (2) JP2002524526A (ko)
KR (1) KR100703253B1 (ko)
CN (2) CN1201812C (ko)
AR (2) AR022382A1 (ko)
AT (2) ATE432707T1 (ko)
AU (1) AU765073B2 (ko)
BR (1) BR9913737A (ko)
CA (1) CA2344151A1 (ko)
CO (1) CO5140070A1 (ko)
CZ (1) CZ302908B6 (ko)
DE (3) DE19842415A1 (ko)
DK (2) DK1113809T3 (ko)
ES (2) ES2327331T3 (ko)
HU (1) HUP0103521A3 (ko)
ID (1) ID29226A (ko)
IL (2) IL141516A0 (ko)
MY (1) MY129572A (ko)
NO (1) NO331734B1 (ko)
NZ (1) NZ510040A (ko)
PE (1) PE20001046A1 (ko)
PL (1) PL201902B1 (ko)
PT (2) PT1466615E (ko)
RU (1) RU2227041C2 (ko)
SI (1) SI1113809T1 (ko)
SK (1) SK287012B6 (ko)
TR (1) TR200100765T2 (ko)
TW (1) TW576744B (ko)
WO (1) WO2000015244A2 (ko)
ZA (1) ZA200103073B (ko)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
SK9072003A3 (en) * 2001-01-09 2003-11-04 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
EP1481678A4 (en) * 2002-03-05 2009-12-30 Eisai R&D Man Co Ltd ANTITUMORAL AGENT CONTAINING A SULFONAMIDE-CONTAINING HETEROCYCLIC COMPOUND AND AN ANGIOGENESIS INHIBITOR
RS52918B (en) 2004-04-02 2014-02-28 The Regents Of The University Of California PROCEDURES AND MIXTURES FOR TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH ALFA V BETA 5 INTEGRINE
KR101399591B1 (ko) * 2005-11-02 2014-06-18 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 동시 화학요법 및 면역요법
US20110165150A1 (en) * 2006-01-18 2011-07-07 Merck Patent Gmbh Isolated organ perfusion combination therapy of cancer
AU2007207465B2 (en) * 2006-01-18 2012-12-06 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
PT2101805E (pt) 2007-01-18 2013-01-31 Merck Patent Gmbh Terapia específica e medicamento usando ligandos integrina para tratar o cancro
JP5341889B2 (ja) 2007-07-17 2013-11-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作された抗αVインテグリンハイブリッド抗体
WO2010051667A1 (zh) * 2008-11-10 2010-05-14 复旦大学 一种环肽纳米管药物组合物及其应用
WO2010057596A2 (en) * 2008-11-20 2010-05-27 Merck Patent Gmbh New therapy and medicament using integrin ligands for treating cancer
NZ597339A (en) 2009-05-25 2013-10-25 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
US10087252B2 (en) 2009-07-24 2018-10-02 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with αvβ5 integrin
EP2509583B1 (en) 2009-12-10 2019-05-15 Merck Patent GmbH Pharmaceutical composition comprising oligopeptides, preferably cilengitide
KR20130092561A (ko) 2010-07-16 2013-08-20 메르크 파텐트 게엠베하 유방암 및/또는 뼈 전이의 치료에 사용하기 위한 펩티드
WO2012069149A1 (en) 2010-11-23 2012-05-31 Merck Patent Gmbh Solution comprising cyclic oligopeptides
LT2672994T (lt) 2011-02-11 2018-07-25 Merck Patent Gmbh Anti-alfa-v integrino antikūnas, skirtas prostatos vėžio gydymui
WO2012110200A1 (en) * 2011-02-18 2012-08-23 Merck Patent Gmbh Cyclic peptide cyclo (l -arginyl - glycyl - l -aspartyl - d - phenylalanyl - n-methyl - l -valyl), compositions thereof, and use thereof in methods for treating graft -versus - host disease
ES2720477T3 (es) 2011-06-09 2019-07-22 Merck Patent Gmbh Tratamiento de cánceres y metástasis con suspensiones de Cilengitide en portador
US20130230485A1 (en) * 2012-03-01 2013-09-05 Kathleen E. Rodgers Methods for Treating Patients Undergoing Multi-Cycle Chemotherapy
CN103333227B (zh) * 2013-06-07 2015-10-07 东南大学 转移肿瘤缺失蛋白小分子环肽抑制剂及其制备方法与应用
JP2019533139A (ja) 2016-09-08 2019-11-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ネフローゼ症候群を診断及び処置するための方法
JP2019208422A (ja) * 2018-06-04 2019-12-12 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー ヒアルロニダーゼを含む新規な組換えエキソソーム及びその用途
GB201911816D0 (en) * 2019-08-16 2019-10-02 Univ London Queen Mary Treatment
GB202103122D0 (en) * 2021-03-05 2021-04-21 Univ London Queen Mary Treatment

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04367367A (ja) 1991-06-11 1992-12-18 Nkk Corp ロータリノズル
AU674553B2 (en) 1992-10-14 1997-01-02 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2150550A1 (en) 1992-12-01 1994-06-09 Melissa S. Egbertson Fibrinogen receptor antagonists
WO1995032710A1 (en) 1994-05-27 1995-12-07 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption
EP0762882A4 (en) 1994-06-29 2002-09-11 Smithkline Beecham Corp Vibronectin Receptor Antagonists
BR9508178A (pt) 1994-06-29 1997-11-18 Smithkline Beecham Corp Antagonistas de receptor de vitronectina
DK0710657T3 (da) 1994-11-02 1999-05-25 Merck Patent Gmbh Adhæsionsreceptor-antagonister
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE19548709A1 (de) * 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
JPH09208571A (ja) * 1996-02-02 1997-08-12 Takeda Chem Ind Ltd アルキリデンシクロヘキサン誘導体
AU2438297A (en) * 1996-05-09 1997-11-26 Alcon Laboratories, Inc. Combinations of angiostatic compounds
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
EP0951295B1 (en) * 1996-05-31 2010-06-09 The Scripps Research Institute Compositions for use in inhibiting of alpha-v-beta3 mediated angiogenesis
JPH1081631A (ja) * 1996-07-17 1998-03-31 Takeda Chem Ind Ltd 癌転移または再発抑制剤
DE19629817A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19629816A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
UA60311C2 (uk) 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
WO1998031359A1 (en) * 1997-01-17 1998-07-23 Merck & Co., Inc. Integrin antagonists
DE19850131A1 (de) 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon- und Chromanonderivate

Also Published As

Publication number Publication date
CN1329499A (zh) 2002-01-02
WO2000015244A3 (de) 2000-06-22
ES2241363T3 (es) 2005-10-16
ID29226A (id) 2001-08-16
ATE432707T1 (de) 2009-06-15
BR9913737A (pt) 2001-06-05
AR078175A2 (es) 2011-10-19
PE20001046A1 (es) 2000-10-14
CZ302908B6 (cs) 2012-01-18
PL201902B1 (pl) 2009-05-29
DE19842415A1 (de) 2000-03-23
PL348026A1 (en) 2002-05-06
EP1466615A1 (de) 2004-10-13
KR100703253B1 (ko) 2007-04-03
NO20011308D0 (no) 2001-03-15
CZ2001932A3 (cs) 2001-09-12
NO20011308L (no) 2001-03-15
SI1113809T1 (en) 2005-10-31
CN1636590A (zh) 2005-07-13
RU2227041C2 (ru) 2004-04-20
IL141516A0 (en) 2002-03-10
WO2000015244A2 (de) 2000-03-23
HUP0103521A3 (en) 2002-05-28
NO331734B1 (no) 2012-03-12
SK287012B6 (sk) 2009-09-07
JP2002524526A (ja) 2002-08-06
PT1466615E (pt) 2009-09-07
HUP0103521A2 (hu) 2002-02-28
AR022382A1 (es) 2002-09-04
TR200100765T2 (tr) 2001-08-21
MY129572A (en) 2007-04-30
ZA200103073B (en) 2002-08-21
US6683051B1 (en) 2004-01-27
NZ510040A (en) 2003-12-19
PT1113809E (pt) 2005-08-31
CN1201812C (zh) 2005-05-18
EP1466615B1 (de) 2009-06-03
DK1113809T3 (da) 2005-08-08
KR20010073155A (ko) 2001-07-31
CA2344151A1 (en) 2000-03-23
AU5975899A (en) 2000-04-03
JP2011252012A (ja) 2011-12-15
ATE292470T1 (de) 2005-04-15
AU765073B2 (en) 2003-09-11
DE59915033D1 (de) 2009-07-16
CO5140070A1 (es) 2002-03-22
EP1113809A2 (de) 2001-07-11
EP1113809B1 (de) 2005-04-06
CN100352494C (zh) 2007-12-05
SK3372001A3 (en) 2001-11-06
IL141516A (en) 2009-09-22
DE59911881D1 (de) 2005-05-12
ES2327331T3 (es) 2009-10-28
TW576744B (en) 2004-02-21

Similar Documents

Publication Publication Date Title
ID23299A (id) Formulasi-formulasi farmasi
ID27415A (id) Komposisi farmaseutik
NO20005218L (no) Farmasöytisk aerosolpreparat
IS5953A (is) Lyfjablöndur úr örgerðum eplerenonum
NO20005913L (no) Legemiddelsammensetning
DK1466615T3 (da) Farmaceutisk præparat
NO20012915D0 (no) Ny farmasöytisk formulering
ID29089A (id) Sediaan farmasi moksifloksasin
NO20005399D0 (no) Farmasøytisk preparat
NO992692L (no) Nefadozon doseringsform
EE200200150A (et) Preparaat
ID27201A (id) Komposisi farmasi
NO20022606D0 (no) Farmasöytiske kombinasjoner
NO20010089D0 (no) Farmasöytisk levotyroksinpreparat
DE69928344D1 (de) Pharmazeutisches Implantat
DE69926012D1 (de) Arzneizubereitungen
DE69906934D1 (de) Arzneizubereitungen
IS5877A (is) Ný efnablanda
IS5879A (is) Ný efnablanda
FI3862U1 (fi) Geelimuotoinen farmaseuttinen valmiste
DK1041984T3 (da) Drikbart farmaceutisk præparat
SE9803952D0 (sv) Pharmaceutical formulation
SE9800330D0 (sv) Pharmaceutical compositions
FI981567A0 (fi) Farmaseuttiset koostumukset
SE9800052D0 (sv) Pharmaceutical compositions